ProShare Advisors LLC Purchases 3,298 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

ProShare Advisors LLC lifted its position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 30.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,226 shares of the company’s stock after acquiring an additional 3,298 shares during the period. ProShare Advisors LLC’s holdings in Olema Pharmaceuticals were worth $83,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in OLMA. Bain Capital Life Sciences Investors LLC purchased a new stake in shares of Olema Pharmaceuticals in the 4th quarter worth approximately $43,551,000. Lightspeed Management Company L.L.C. purchased a new stake in shares of Olema Pharmaceuticals in the 4th quarter worth approximately $11,257,000. Paradigm Biocapital Advisors LP grew its stake in shares of Olema Pharmaceuticals by 32.7% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 7,304,970 shares of the company’s stock worth $42,588,000 after buying an additional 1,801,370 shares during the last quarter. Avoro Capital Advisors LLC purchased a new stake in shares of Olema Pharmaceuticals in the 4th quarter worth approximately $9,631,000. Finally, Millennium Management LLC grew its stake in shares of Olema Pharmaceuticals by 1,154.4% in the 4th quarter. Millennium Management LLC now owns 979,219 shares of the company’s stock worth $5,709,000 after buying an additional 901,159 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on OLMA. JPMorgan Chase & Co. cut their price target on Olema Pharmaceuticals from $30.00 to $28.00 and set an “overweight” rating on the stock in a research note on Friday, March 28th. Oppenheimer cut their price target on Olema Pharmaceuticals from $25.00 to $22.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 14th. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Monday, April 28th. Finally, The Goldman Sachs Group cut their price target on Olema Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th.

Olema Pharmaceuticals Price Performance

OLMA stock opened at $4.05 on Wednesday. The company has a market cap of $277.11 million, a P/E ratio of -1.85 and a beta of 2.03. Olema Pharmaceuticals, Inc. has a 1 year low of $2.86 and a 1 year high of $16.62. The stock’s fifty day moving average price is $4.45 and its 200-day moving average price is $5.52.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its earnings results on Tuesday, May 13th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. As a group, analysts expect that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.

Olema Pharmaceuticals Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.